A
A.C. Pouleur
Researcher at Cliniques Universitaires Saint-Luc
Publications - 12
Citations - 561
A.C. Pouleur is an academic researcher from Cliniques Universitaires Saint-Luc. The author has contributed to research in topics: Heart failure & Muscle hypertrophy. The author has an hindex of 5, co-authored 12 publications receiving 376 citations. Previous affiliations of A.C. Pouleur include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule.
Alexis Werion,Leila Belkhir,Leila Belkhir,Marie Perrot,Gregory Schmit,Selda Aydin,Selda Aydin,Zhiyong Chen,A Penaloza,Julien De Greef,Julien De Greef,Halil Yildiz,Halil Yildiz,Lucie Pothen,Lucie Pothen,Jean Cyr Yombi,Jean Cyr Yombi,Joseph Dewulf,Anaïs Scohy,Ludovic Gerard,Ludovic Gerard,Xavier Wittebole,Xavier Wittebole,Pierre-François Laterre,Pierre-François Laterre,Sara E. Miller,Olivier Devuyst,Olivier Devuyst,Olivier Devuyst,Michel Jadoul,Johann Morelle,Johann Morelle,Frank Aboubakar,Souad Acid,Nadia Amini,Sarah Bailly,Christophe Beauloye,Diego Castanares-Zapatero,Emmanuel Coche,Christine Collienne,Pascale Cornette,Isabelle De Brauwer,Mélanie Dechamps,Florence Dupriez,Antoine Froidure,Quentin Garnir,Bernhard Gerber,Benoît Ghaye,Isabelle Gilard,Sophie Gohy,Charles Grégoire,Philippe Hantson,Luc-Marie Jacquet,Benoit Kabamba,Shakeel Kautbally,Nicolas Lanthier,Fatima Larbaoui,Giuseppe Liistro,Frédéric Maes,Virginie Montiel,Benny Mwenge,Sophie F. Piérard,Charles Pilette,A.C. Pouleur,Amaury Sogorb,Peter Stärkel,Hector Rodriguez-Villalobos,Maximilien Thoma,Olivier Van Caeneghem,David Vancraeynest +69 more
TL;DR: The data establish that SARS-CoV-2 causes specific manifestations of proximal tubule dysfunction and provide novel insights into COVID-19 severity and outcome and establish that coronavirus disease 2019 is commonly associated with kidney damage.
Journal ArticleDOI
Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy.
Maja Cikes,Sergio Sanchez-Martinez,Brian Claggett,Nicolas Duchateau,Gemma Piella,Constantine Butakoff,A.C. Pouleur,Dorit Knappe,Tor Biering-Sørensen,Tor Biering-Sørensen,Valentina Kutyifa,Arthur J. Moss,Kenneth M. Stein,Scott D. Solomon,Bart Bijnens +14 more
TL;DR: This work tested the hypothesis that a machine learning algorithm utilizing both complex echocardiographic data and clinical parameters could be used to phenogroup a heart failure cohort and identify patients with beneficial response to cardiac resynchronization therapy (CRT).
Journal ArticleDOI
Enhanced Expression of β3-Adrenoceptors in Cardiac Myocytes Attenuates Neurohormone-Induced Hypertrophic Remodeling Through Nitric Oxide Synthase
Catharina Belge,Joanna Hammond,Emilie Dubois-Deruy,Boris Manoury,Julien Hamelet,Christophe Beauloye,Andreas Markl,A.C. Pouleur,Luc Bertrand,Hrag Esfahani,Karima Jnaoui,Konrad R. Götz,Viacheslav O. Nikolaev,Annelies Vanderper,Paul Herijgers,Irina Lobysheva,Guido Iaccarino,Denise Hilfiker-Kleiner,Geneviève Tavernier,Dominique Langin,Chantal Dessy,Jean-Luc Balligand +21 more
TL;DR: Cardiac-specific overexpression of &bgr;3-AR does not affect cardiac morphology at baseline but inhibits the hypertrophic response to neurohormonal stimulation in vivo and in vitro, through a NOS-mediated mechanism.
Journal ArticleDOI
Dyssynchrony and the Risk of Ventricular Arrhythmias
Valentina Kutyifa,Valentina Kutyifa,A.C. Pouleur,Dorit Knappe,Amin Al-Ahmad,Michal Gibinski,Paul J. Wang,Scott McNitt,Béla Merkely,Ilan Goldenberg,Scott D. Solomon,Arthur J. Moss,Wojciech Zareba +12 more
TL;DR: Baseline LV dyssynchrony did not predict VT/VF/death or VT/F in mild heart failure patients with or without LBBB, and CRT-induced improvement of LV dySSynchrony was associated with significant reduction of ventricular arrhythmias in patients with L BBB.
Journal ArticleDOI
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
A.C. Pouleur,Stefan D. Anker,Stefan D. Anker,Dulce Brito,Oana Brosteanu,Dirk Hasenclever,Barbara Casadei,Frank Edelmann,Gerasimos Filippatos,Damien Gruson,Ignatios Ikonomidis,Renaud Lhommel,Masliza Mahmod,Stefan Neubauer,Alexandre Persu,Bernhard Gerber,Stefan K. Piechnik,Burkert Pieske,Elisabeth Pieske-Kraigher,Fausto J. Pinto,Piotr Ponikowski,Michele Senni,Jean Noël Trochu,Nancy Van Overstraeten,Rolf Wachter,Jean-Luc Balligand +25 more
TL;DR: The Beta3‐LVH trial will test the hypothesis that the β3 adrenergic receptor agonist mirabegron will improve LV hypertrophy and diastolic function in patients with hypertensive structural heart disease at high risk for developing heart failure with preserved ejection fraction.